drugset / Trial / NCT05217355
A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is intended to evaluate the efficacy and safety of MBA-P01 compared to placebo in treatment of glabellar lines.
Timeline
- Start
- 2021-12-28
- Primary completion
- 2022-06-22
- Completion
- 2022-06-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MBA-P01 | Protein / enzyme biologic | 20 iu | Other |
Indications
No indication recorded.